The Effects of Cannabinoids on Ischemic Stroke-Associated Neuroinflammation: A Systematic Review

Overview

Journal J Neuroimmune Pharmacol

Date 2025 Feb 3

PMID 39899062

Authors

Eman A Alraddadi

Faisal F Aljuhani

Ghadah Y Alsamiri

Salwa Y Hafez

Ghaida Alselami

Daniyah A Almarghalani

Faisal F Alamri

Affiliations

Soon will be listed here.

Abstract

Stroke represents a significant burden on global health and the economy, with high mortality rates, disability, and recurrence. Ischemic stroke is a serious condition that occurs when a blood vessel in the brain is interrupted, reducing the blood supply to the affected area. Inflammation is a significant component in stroke pathophysiology. Neuroinflammation is triggered following the acute ischemic ictus, where the blood-brain barrier (BBB) breaks down, causing damage to the endothelial cells. The damage will eventually generate oxidative stress, activate the pathological phenotypes of astrocytes and microglia, and lead to neuronal death in the neurovascular unit. As a result, the brain unleashes a robust neuroinflammatory response, which can further worsen the neurological outcomes. Neuroinflammation is a complex pathological process involved in ischemic damage and repair. Finding new neuroinflammation molecular targets is essential to develop effective and safe novel treatment approaches against ischemic stroke. Accumulating studies have investigated the pharmacological properties of cannabinoids (CBs) for many years, and recent research has shown their potential therapeutic use in treating ischemic stroke in rodent models. These findings revealed promising impacts of CBs in reducing neuroinflammation and cellular death and ameliorating neurological deficits. In this review, we explore the possibility of the therapeutic administration of CBs in mitigating neuroinflammation caused by a stroke. We summarize the results from several preclinical studies evaluating the efficacy of CBs anti-inflammatory interventions in ischemic stroke. Although convincing preclinical evidence implies that CBs targeting neuroinflammation are promising for ischemic stroke, translating these findings into the clinical setting has proven to be challenging. The translation hurdle is due to the essence of the CBs ability to cause anxiety, cognitive deficit, and psychosis. Future studies are warranted to address the dose-beneficial effect of CBs in clinical trials of ischemic stroke-related neuroinflammation treatment.

References

Schabitz W, Giuffrida A, Berger C, Aschoff A, Schwaninger M, Schwab S . Release of fatty acid amides in a patient with hemispheric stroke: a microdialysis study. Stroke. 2002; 33(8):2112-4. DOI: 10.1161/01.str.0000023491.63693.18. View

Ma L, Wang L, Yang F, Meng X, Wu C, Ma H . Disease-modifying effects of RHC80267 and JZL184 in a pilocarpine mouse model of temporal lobe epilepsy. CNS Neurosci Ther. 2014; 20(10):905-15. PMC: 6493031. DOI: 10.1111/cns.12302. View

Jaggar S, Hasnie F, Sellaturay S, Rice A . The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain. 1998; 76(1-2):189-99. DOI: 10.1016/s0304-3959(98)00041-4. View

Knowles M, de la Tremblaye P, Azogu I, Plamondon H . Endocannabinoid CB1 receptor activation upon global ischemia adversely impact recovery of reward and stress signaling molecules, neuronal survival and behavioral impulsivity. Prog Neuropsychopharmacol Biol Psychiatry. 2015; 66:8-21. DOI: 10.1016/j.pnpbp.2015.10.010. View

Jayaraj R, Azimullah S, Beiram R, Jalal F, Rosenberg G . Neuroinflammation: friend and foe for ischemic stroke. J Neuroinflammation. 2019; 16(1):142. PMC: 6617684. DOI: 10.1186/s12974-019-1516-2. View

Ashton J, Rahman R, Nair S, Sutherland B, Glass M, Appleton I . Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain. Neurosci Lett. 2006; 412(2):114-7. DOI: 10.1016/j.neulet.2006.10.053. View

Scherma M, Justinova Z, Zanettini C, Panlilio L, Mascia P, Fadda P . The anandamide transport inhibitor AM404 reduces the rewarding effects of nicotine and nicotine-induced dopamine elevations in the nucleus accumbens shell in rats. Br J Pharmacol. 2011; 165(8):2539-48. PMC: 3423245. DOI: 10.1111/j.1476-5381.2011.01467.x. View

Hillard C, Manna S, Greenberg M, DiCamelli R, Ross R, Stevenson L . Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther. 1999; 289(3):1427-33. View

Benedicto A, Arteta B, Duranti A, Alonso-Alconada D . The Synthetic Cannabinoid URB447 Exerts Antitumor and Antimetastatic Effect in Melanoma and Colon Cancer. Pharmaceuticals (Basel). 2022; 15(10). PMC: 9606960. DOI: 10.3390/ph15101166. View

10.

Zhang Y, Milatovic D, Aschner M, Feustel P, Kimelberg H . Neuroprotection by tamoxifen in focal cerebral ischemia is not mediated by an agonist action at estrogen receptors but is associated with antioxidant activity. Exp Neurol. 2007; 204(2):819-27. PMC: 1913768. DOI: 10.1016/j.expneurol.2007.01.015. View

11.

Liu M, Li H, Xu X, Barnstable C, Zhang S . Comparison of gene expression during in vivo and in vitro postnatal retina development. J Ocul Biol Dis Infor. 2010; 1(2-4):59-72. PMC: 2802513. DOI: 10.1007/s12177-008-9009-z. View

12.

Wen A, Sakamoto K, Miller L . The role of the transcription factor CREB in immune function. J Immunol. 2010; 185(11):6413-9. PMC: 5519339. DOI: 10.4049/jimmunol.1001829. View

13.

Lakhan S, Kirchgessner A, Hofer M . Inflammatory mechanisms in ischemic stroke: therapeutic approaches. J Transl Med. 2009; 7:97. PMC: 2780998. DOI: 10.1186/1479-5876-7-97. View

14.

Passavanti M, Alfieri A, Pace M, Pota V, Sansone P, Piccinno G . Clinical applications of palmitoylethanolamide in pain management: protocol for a scoping review. Syst Rev. 2019; 8(1):9. PMC: 6323836. DOI: 10.1186/s13643-018-0934-z. View

15.

Le Foll B, Tang V, Rueda S, Trick L, Boileau I . Cannabis use disorder: from neurobiology to treatment. J Clin Invest. 2024; 134(20). PMC: 11473150. DOI: 10.1172/JCI172887. View

16.

Clayton P, Hill M, Bogoda N, Subah S, Venkatesh R . Palmitoylethanolamide: A Natural Compound for Health Management. Int J Mol Sci. 2021; 22(10). PMC: 8157570. DOI: 10.3390/ijms22105305. View

17.

Gupta B, Hornick M, Briyal S, Donovan R, Prazad P, Gulati A . Anti-apoptotic and Immunomodulatory Effect of CB2 Agonist, JWH133, in a Neonatal Rat Model of Hypoxic-Ischemic Encephalopathy. Front Pediatr. 2020; 8:65. PMC: 7056833. DOI: 10.3389/fped.2020.00065. View

18.

Mori M, Meyer E, Soares L, Milani H, Guimaraes F, de Oliveira R . Cannabidiol reduces neuroinflammation and promotes neuroplasticity and functional recovery after brain ischemia. Prog Neuropsychopharmacol Biol Psychiatry. 2016; 75:94-105. DOI: 10.1016/j.pnpbp.2016.11.005. View

19.

Alonso-Alconada D, Alvarez F, Goni-de-Cerio F, Hilario E, Alvarez A . Cannabinoid-mediated Modulation of Oxidative Stress and Early Inflammatory Response after Hypoxia-Ischemia. Int J Mol Sci. 2020; 21(4). PMC: 7072925. DOI: 10.3390/ijms21041283. View

20.

Doohan P, Oldfield L, Arnold J, Anderson L . Cannabinoid Interactions with Cytochrome P450 Drug Metabolism: a Full-Spectrum Characterization. AAPS J. 2021; 23(4):91. DOI: 10.1208/s12248-021-00616-7. View